Eli Lilly's Sudden Surge Challenges Novo's Weight Loss Dominance Eli Lilly's surprising comeback in the weight loss market has sent shockwaves through the pharmaceutical industry, threatening to upend Novo Nordisk's early lead.
The company's stock has surged 14% over the past week alone, propelled by promising trial results for its once weekly injection, tirzepatide.
The resurgence of Eli Lilly poses significant challenges to Novo Nordisk, which had been riding high on the success of Wegovy (semaglutide).